These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17435854)

  • 21. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy.
    Asensi V; Martín-Roces E; Carton JA; Collazos J; Maradona JA; Alonso A; Medina M; Aburto JM; Martínez E; Rojo C; Bustillo E; Fernández C; Arribas JM
    Clin Infect Dis; 2004 Jul; 39(2):240-7. PubMed ID: 15307034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients].
    Ena J; Benito C; Llácer P; Pasquau F; Amador C
    Med Clin (Barc); 2004 May; 122(19):721-6. PubMed ID: 15171905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid accumulation product index in HIV-infected patients: a marker of cardiovascular risk.
    Guimarães MMM; Greco DB; Moreira AN; Guimarães NS; Freire CMV; Rohlfs BG; Machado LJC
    Braz J Infect Dis; 2018; 22(3):171-176. PubMed ID: 29684319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study.
    Diaz-Zamudio M; Dey D; LaBounty T; Nelson M; Fan Z; Szczepaniak LS; Hsieh BP; Rajani R; Berman D; Li D; Dharmakumar R; Hardy WD; Conte AH
    J Cardiovasc Magn Reson; 2015 Oct; 17():91. PubMed ID: 26520571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
    AIDS; 2002 Nov; 16(16):2183-93. PubMed ID: 12409740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment.
    Ekali LG; Johnstone LK; Echouffo-Tcheugui JB; Kouanfack C; Dehayem MY; Fezeu L; Nouthe B; Hayes L; Unwin NC; Sobngwi E
    Diabetes Metab; 2013 Feb; 39(1):71-7. PubMed ID: 23153435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance.
    Freitas P; Carvalho D; Santos AC; Mesquita J; Matos MJ; Madureira AJ; Martinez E; Sarmento A; Medina JL
    BMC Infect Dis; 2012 Aug; 12():180. PubMed ID: 22866963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
    Mallon PW; Miller J; Cooper DA; Carr A
    AIDS; 2003 May; 17(7):971-9. PubMed ID: 12700446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Lichtenstein KA; Glueck DH; Gourley PJ; Stamm ER; Scherzinger AL; Eckel RH
    AIDS; 2001 Oct; 15(15):1993-2000. PubMed ID: 11600828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
    Saint-Marc T; Partisani M; Poizot-Martin I; Bruno F; Rouviere O; Lang JM; Gastaut JA; Touraine JL
    AIDS; 1999 Sep; 13(13):1659-67. PubMed ID: 10509567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome.
    Soares LR; da Silva DC; Gonsalez CR; Batista FG; Fonseca LA; Duarte AJ; Casseb J
    Rev Inst Med Trop Sao Paulo; 2015; 57(2):105-10. PubMed ID: 25923888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
    Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents.
    Viganò A; Mora S; Brambilla P; Schneider L; Merlo M; Monti LD; Manzoni P
    AIDS; 2003 Jul; 17(10):1435-41. PubMed ID: 12824780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
    AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus.
    Ergun-Longmire B; Lin-Su K; Dunn AM; Chan L; Ham K; Sison C; Stavola J; Vogiatzi MG
    Endocr Pract; 2006; 12(5):514-21. PubMed ID: 17014060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.
    Blümer RM; van der Valk M; Ackermans M; Endert E; Serlie MJ; Reiss P; Sauerwein HP
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1097-104. PubMed ID: 19690066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
    Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P
    AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.